Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response

Golale Rostami1 | Dlnya Assad2 | Fatemeh Ghadyani3 | Mohammad Hamid1 | Amirhossien Karami1 | Hasan Jalaeikhoo4 | Ramezan Ali Kalahroodi5

Abstract

Background: Glutathione S-transferases (GSTs) polymorphisms may impact on chronic myeloid leukemia (CML) risk or heterogeneous responses to Imatinib mesylate (IM). The aim of this study was to evaluate the correlation between GSTs polymorphisms and CML risk, treatment response.

Methods: We genotyped GSTM1, GSTT1 null deletion polymorphisms, and GSTP1 Ile105Val polymorphism by PCR methods and BCR-ABL transcripts were analyzed by qRT-PCR in 104 CML patients and 104 sex- and age-matched healthy individuals.

Results: Individual analysis showed significant association of GSTM1 (p = 0.008; OR = 0.46; 95% CI: 0.26–0.82) and GSTP1 genes (p = 0.04; OR = 1.56; 95% CI: 1.016–2.423) with CML risk. The combined analysis indicated that GSTM1 null/GSTT1 present, GSTM1 null/GSTP1 M* (AG/GG) as well as GSTT1 present/GSTP1M* genotype were associated with CML risk (ORg(−): 2.28; 95% CI: 1.29–4.04; ORgg: 2.85; 95% CI: 1.36–5.97; OR(−)g: 1.75; 95% CI: 0.99–3.06, respectively). The proportion of CML cancer attributable to the interaction of smoking and GSTM1 null, GSTT1 null, and GSTP1 M* was 42%, 39%, and 13%, respectively. Patients with GSTM1 null and GSTP1 AG/GG genotype had significantly a lower rate of MMR achievement (p = 0.00; p = 0.009 respectively). Event-free survival (EFS) percentage was similar between GSTM1 null and GSTM1 present patients (p = 0.21).

Conclusion: Our study suggests the influence of GSTM1 and GSTP1 polymorphisms on CML risk and treatment response. The interaction between GSTs polymorphisms and smoking plays a significant role on CML susceptibility.

KEYWORDS

chronic myeloid leukemia, genetic polymorphisms, glutathione S-transferases, smoking status, treatment responses
Chronic myeloid leukemia (CML) is a myeloproliferative disease and an outcome of the reciprocal translocation t (9;22) (q34;q11) or the BCR-ABL1 fusion gene (Kassogue et al., 2014; Rostami, Hamid, Yaran, Khani, & Karimipoor, 2015). The tyrosine kinase inhibitor (TKI), Imatinib mesylate (IM) is a potent Bcr-Abl1–targeting drug with remarkable clinical benefits. Despite the excellent results achieved with IM regarding to the improvement of quality of life and patient survival, almost 40% of CML patients will finally fail IM treatment and demand second-generation (2G) TKIs such as nilotinib or dasatinib (Davies et al., 2014; Francis et al., 2013). However, treatment failure to 2G TKIs as initial therapy due to toxicity has been reported (Eghether, 2013). Development of resistance to TKIs in CML has been assigned to Bcr-Abl1-dependent and -independent mechanisms, and mutations of the ABL1 kinase domain are the most general cause of resistance (Rostami et al., 2015). It has also been reported that polymorphism in genes associated to drug bioavailability and metabolizing enzymes may affect treatment outcome (Weich et al., 2016). Earlier association studies have identified the roles of polymorphic variants in different crucial genes associated with predisposing individuals to CML, with incompatible results (Bruzzone-Giovanelli et al., 2015; He et al., 2014). These incompatibilities may be due to lifestyle factors, ethnic differences, environmental exposures in population cohorts studied (Davies et al., 2014; Özten, Sunguroğlu, & Bosland, 2012). Glutathione S-transferase (GST) genes, an important family of phase II metabolizing enzymes, catalyze the conjugation of a large spectrum of endogenous and exogenous compounds, including carcinogens, anticancer drugs, and their metabolites with reduced glutathione, thus enabling their detoxification and elimination (Hayes, Flanagan, & Jowsey, 2005). Detoxification of activated carcinogens by hydrolysis, reduction or oxidation protects the cells from producing of DNA adducts, genomic instability, and finally the initiation of cancer (Dusinska et al., 2012; Laborde, 2010). It has been suggested that individual inherited genetic differences in the ability to metabolize carcinogens correlated with polymorphism in detoxification enzymes may influence in carcinogen metabolism and cancer susceptibility (Taspinar et al., 2008; Yaya et al., 2014). Whole-gene deletion polymorphisms of GSTM1 (OMIM accession number:*138350) and GSTT1 (OMIM accession number:*600436) genes and the single nucleotide polymorphism (SNP) in GSTP1 c. 313 A>G (p. 105Ile>Val; rs1695) (OMIM accession number:*134660) lead to the absence or decreased detoxification ability of enzymes, their dysfunction, and finally may impact on the risk of cancer development, heterogeneous drug responsiveness (Davies et al., 2014; Hollman, Tchounwou, & Huang, 2016; Özten et al., 2012). Several studies determined only the role of GST polymorphisms on CML susceptibility (Al-Achkar, Azeiz, Moassass, & Wafa, 2014; He et al., 2014; Özten et al., 2012) and some studies assessed their impact on treatment response (Davies et al., 2014; Kassogue et al., 2014). A recent study has evaluated the effect of GST polymorphisms on CML susceptibility and treatment response, but the interaction between these genes and environmental exposures or risk factors such as cigarette smoke was not evaluated in CML development (Weich et al., 2016). Little is known about the relation between GST polymorphisms and smoking associated with the risk of CML development, predicting treatment response, and clinical outcome simultaneously. Therefore, our overall aim of this work was to identify, for the first time, the correlation between GSTs genetic polymorphisms and CML cancer risk, treatment response and pattern its interactions with smoking as genetic modifiers in the etiologic of CML disease in the Iranian population.

2 | MATERIAL AND METHODS

2.1 | Ethical compliance

Informed consent from patients, as well as from controls was obtained. The study was approved by Pasteur Institute of Iran Ethics Committee.

2.2 | Study subjects

The study population was composed of 104 patients diagnosed with CML at Arad Hospital and Saba Oncology Clinic, and under treatment with TKI (Imatinib 400,800 mg/day) with a mean of follow up of 61.13 months, ranging from four to 216 months. All of the patients were in the chronic phase (CP). BCR-ABL1 transcripts and total ABL1 as internal control were measured by quantitative real-time polymerase chain reaction (qRT-PCR), according to log reduction international scale (SI) as previously described (Cross., 2009; Müller et al., 2009). In addition, 104 sex- and age-matched healthy unrelated individuals without history of cancer or other chronic diseases were recruited from Arad and Torfeh Hospitals. The smokers were defined as individuals who have smoked at least one package of cigarettes daily; nonsmokers were defined as individuals who have never smoked. The patient and control groups were Iranian, and had the same ethnicity. Demographic data of the studied subjects are shown in Table 1.

2.3 | Definition of treatment response

Response definitions include major cytogenetic response (MCyR), complete cytogenetic response (CCyR), major molecular response (MMR), complete molecular response (CMR), and also disease phases include chronic phase (CP), accelerate phase (AP), and blastic phase (BP) were defined according to European Leukemia Net (ELN) criteria.
(Baccarani et al., 2009, 2013, 2006). Optimal ELN response by cytogenetic and molecular responses were described previously (Baccarani et al., 2009).

### 2.4 Genotype analysis

Genomic DNA was extracted from EDTA peripheral blood using salting-out method (Miller, Dykes, & Polesky, 1988). A multiplex PCR was used for GSTT1 (NM_000853.3) and GSTM1 (NG_009246.1) amplification with β-globin gene as an internal positive control. The primers used were described in Öztên et al., 2012. The absence of PCR products for GSTM1 and GSTT1 (219 and 480 bp respectively) in the presence of β-globin PCR product (268bp) indicated the null genotype for each. The genotyping of GSTP1 c.313 A>G polymorphism (NG_012075.1) was carried out by using the polymerase chain reaction/ restriction fragment length polymorphism (PCR-RFLP) method with Alw26I restriction enzyme (Thermo Fisher). The primer sequence and the PCR reaction conditions for GSTP1 amplification were followed as defined previously (Soylemez, Akbas, Seyrek, Mutluhan, & Camdeviren, 2006)). The 436 bp PCR product of GSTP1 Ile105Val was digested into fragments of 222 bp and 107 bp and which was indicative of homozygous mutant genotype (GG), the presence of three bands of 329 bp, 222 bp, and 107 bp indicated the heterozygous genotype (AG), and the appearance of two fragments at 329 bp and 107 bp represented the wild genotype (AA). To ensure quality control, a 10% random sample of the total was genotyped twice by two different persons; genotypes were 100% concordant.

### 2.5 Statistical analysis

To evaluate the differences in the distribution of demographic features between the cases and controls, we used chi-square test ($\chi^2$ test) and $t$ test to compare the mean of age. Hardy–Weinberg equilibrium was carried out by comparing the observed and expected genotype frequencies for the GSTP polymorphism using a $\chi^2$ test. The same test was used to compare the frequency of GSTs genotypes among cases and controls, and also to measure their influence on response to treatment. In addition, the odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. In order to evaluate disease penetrance for GSTP1, the standard genetic models (recessive, dominant, and additive) were used.

### Table 1

Demographic characteristics of the CML patients and control group

|                      | CML patients | Controls | $p$-value |
|----------------------|--------------|----------|-----------|
| **Number**           | 104          | 104      |           |
| **Sex [n (%)]**      |              |          |           |
| Males                | 55 (52.9%)   | 57 (54.8%)| 0.78      |
| Females              | 49 (47.1%)   | 47 (45.2%)|           |
| **Age (years)**      |              |          |           |
| $SD \pm$ Mean        | 15.1 ± 43.8  | 15.57 ± 44.99 | 0.57     |
| **Smoking status [n (%)]** |        |          |           |
| Smokers              | 57 (54.80%)  | 31 (29.80%)| 0         |
| Nonsmokers           | 47 (45.2%)   | 73 (70.2%)|           |

Abbreviation: $SD$, standard deviation.

### 3 RESULTS

#### 3.1 Demographic features of the studied subjects

In the current study, 104 CML patients and 104 controls were evaluated. There was no significant difference among patients and controls regarding gender distribution and the mean of age ($p > 0.05$), but there was significant difference between the two group in terms of smoking status as higher percentage (54.8% vs. 29.8%) of patients was smokers than controls ($p = 0$) (Table 1).
TABLE 2  Association analyses between individual GST polymorphisms and CML risk

| Genes  | Genotype/Allele | Patients N = 104(%) | Controls N = 104(%) | Genetic models | p-value | OR (95% CI) |
|--------|----------------|---------------------|---------------------|----------------|---------|-------------|
| GSTM1a | Present        | 34 (32.7%)          | 53 (51%)            | Recessive      | 0.008   | 0.46 (0.26–0.82) |
|        | Null           | 70 (67.3%)          | 51 (49%)            | Recessive      |         |             |
| GSTT1b | Present        | 101 (97.1%)         | 103 (99%)           | Recessive      | 0.31    | 0.32 (0.03–3.19) |
|        | Null           | 3 (2.09%)           | 1 (1%)              | Recessive      | 0.07    | 0.38 (0.13–1.14) |
| GSTP1c | AA             | 54 (51.92%)         | 66 (63.5%)          | Recessive      | 0.07    | 0.38 (0.13–1.14) |
|        | AG             | 38 (36.54%)         | 33 (31.7%)          | Dominant       | 0.09    | 0.62 (0.35–1.08) |
|        | GG             | 12 (11.5%)          | 5 (4.8%)            | Additive       | 0.04    | 1.569 (1.016–2.423) |
|        | A              | 146 (70.19%)        | 165 (79.33%)        |                | 0.03    | 0.61 (0.39–0.96) |
|        | G              | 62 (29.81%)         | 43 (20.67%)         |                |         |             |

Bold indicate significant values. Abbreviations: OR, odds ratio; CI, confidence interval.

aGSTM1 (GenBank accession number: NG_009246.1).
bGSTT1 (NM_000853.3).
cGSTP1 (NG_012075.1).

3.2  |  GSTM1, GSTT1, and GSTP1 genotypes distribution and risk of CML cancer

The frequencies of GST genotypes are shown in Table 2. The frequencies of the GSTT1 null (GSTT1−) genotype in CML patients and controls were similar (2.09% vs. 1%). In contrast, the frequency of GSTM1 null (GSTM1−; null genotype has no enzyme activity) genotype in CML patients was significantly higher than controls (67.3% vs. 49%). To analyze the association between GST polymorphisms and CML risk, we used a recessive genetic model for GSTM1 and GSTT1 genes. Analysis of recessive model showed significant difference for the individual genotype of GSTM1 (p = 0.008; OR: 0.46; 95% CI: 0.26–0.82), this suggests that individual genotype of GSTM1 null is associated with CML development. There was no significant difference for the individual genotype of GSTT1 between the patients and controls (p = 0.31; OR: 0.32; 95% CI: 0.03–3.19). We used different genetic models for GSTP1 gene and showed a trend significance (p = 0.04), following an additive model (GG>AG>AA), this suggests 1.569 fold increased risk for GG (Table 2). GSTP1 polymorphism was in agreement with the Hardy–Weinberg equilibrium for patients and controls (p = 0.19; p = 0.73).

3.3  |  Gene–gene interactions for combinations of GSTs genotypes and CML cancer risk

We analyzed the joint effect of GST polymorphisms or interaction between genes by logistic regression to evaluate double combined genotypes with considering additive model for GSTP1 gene and recessive model for GSTT1, GSTM1 genes (Table 3). Frequencies of GSTM1 null/GSTT1 present, GSTM1 null/GSTP1 M* as well as GSTT1 present/GSTP1 M* genotype combinations were significantly increased in patients (66.34%, 41.35% and 48.08%) than the controls (48.07%, 18.27% and 35.58%, respectively). This shows that these combined genotypes are associated with CML risk (p = 0.004; ORg(−): 2.28; 95% CI: 1.29–4.04; p = 0.005; ORgg: 2.85; 95% CI: 1.36–5.97; p = 0.05; OR(−)g: 1.75; 95% CI: 0.99–3.06). Joint ORs for gene–gene combinations and RERI for GSTs and CML risk compared with the referent group are presented in Table 3. ORs for GSTM1 (null and present) and GSTT1 null, GSTM1 (null and present) and GSTP1 AA as well as GSTT1 null and GSTP1 M*/AA were not associated with CML development. The RERI for GSTM1-GSTP1 was more than zero indicating more than additive effect between these genes (RERI: 2.32), so the interaction was positive or superadditive. The RERI for GSTT1- GSTP1 was negative or subadditive (RERI: −0.74).

3.4  |  Gene–environment interactions between GSTs genotype and smoking for CML risk

Joint ORs, RERIOR, AP, and SI for gene–smoking combinations and CML risk are presented in Table 4. The reference group: subjects unexposed to smoking and genetic risk as being 1.0, the ORs (ORge) evaluating the impact of joint exposure to smoking and GSTM1 null or GSTP1 M* genotype was insignificantly higher than the ORs (ORge) evaluating the impact of each factor in the lack of the other. The OR (ORge) estimating the impact of joint exposure to smoking and GSTT1 null was insignificantly higher than the effect of each factor alone. The proportion of CML cancer attributable to the interaction of smoking and GSTM1 null was 42%.
and was 39%, 13% for GSTT1 null and GSTP1 M*, respectively (Table 4). The RERI, the relative excess risk due to interaction of GSTM1−Smoking, and GSTT1−Smoking was more than zero suggesting more than additive effect between these genes and smoking risk (RERI = 2.756; AP = 0.42; SI = 1.99; RERI = 1.26; AP = 0.39; SI = 2.39 respectively). The RERI for GSTP1−Smoking was 0.58 indicating a positive interaction between this gene and smoking risk, but with less effect than GSTM1 and GSTT1.

### 3.5 Evaluating of treatment response and clinical outcome

In order to estimate the association between GSTs polymorphism and treatment response and clinical outcome, we calculated two endpoints by Kaplan–Meier plots for GSTM1. Patients with GSTM1-null genotype had significantly a lower rate of MMR achievement compared to GSTM1present patients (p = 0.00) (Figure 1a). No association was detected for GSTT1 polymorphism. No significant difference was observed between patients with GSTM1-null and GSTM1-present genotype regarding EFS percentage (p = 0.21) (Figure 1b), and also no association was found for probability of EFS in GSTP1 genotype (data not shown). Furthermore, we compared different genotypes based on the achievement of optimal ELN response by cytogenetic and molecular responses at 3 and 6 months (Table 5). Patients with GSTM1/null genotype significantly had lower rate of MCyR and CCyR at 3 and 6 months (p = 0.01; p = 0.00 respectively), regarding molecular response, this difference was significant between patients with GSTM1/null and GSTM1/present at 3 and 6 months (p = 0.00) (Table 5). Patients with GSTP1 AG/GG genotype had lower rate of CCyR at 6 month (p = 0.03). No significant difference was observed for MCyR rate at 3 month (p = 0.08). Patients with GSTP1 AG/GG genotype had inferior rate of molecular response at 3 and 6 months (p = 0.05; p = 0.009) (Table 5).

### 4 DISCUSSION

Although a number of studies have been carried out in different ethnic populations to evaluate the role of GSTs polymorphisms on CML susceptibility, but significance of association is still controversial. These inconsistencies

| Gene−Gene interactions for different combinations of GSTM1, GSTT1, and GSTP1 genotypes and CML cancer risk |
|--------------------------------------------------|
| Genotype combination | Cases [n(%)] N = 104 | Controls [n(%)] N = 104 | p-value ($\chi^2$, df) | OR | 95% CI |
|----------------------|---------------------|---------------------|---------------------|-----|--------|
| **GSTM1**|**GSTT1**<sup>b</sup> | Null/Null | 1 (0.96) | 1 (0.96) | (df = 1) | 1 | OR<sub>gg</sub> | 1.65 | 0.1‐27.40 |
| | | Null/Present | 69 (66.34) | 50 (48.07) | (8.2, 1) | 0.004 | OR<sub>(‐)g</sub> | 2.28 | 1.29‐4.04 |
| | | Present/Null | 2 (1.92) | 0 (0) | (df = 1) | 0.15 | OR<sub>(‐)g</sub> | — | — |
| | | Present/present | 32 (30.77) | 53 (50.96) | Ref | Ref | 1 | — |
| **Additive Interaction (RERI)** | | | | | RERI<sub>OR</sub> | 0.37 |
| **GSTM1**|**GSTP1**<sup>c</sup> | Null/M* | 43 (41.35) | 19 (18.27) | (7.891, 1) | 0.005 | OR<sub>gg</sub> | 2.85 | 1.36‐5.97 |
| | | Null/AA | 27(25.96) | 32 (30.77) | (0.027, 1) | 0.86 | OR<sub>(‐)g</sub> | 1.06 | 0.51‐2.18 |
| | | Present/ M* | 7 (6.73) | 19 (18.27) | (2.302, 1) | 0.12 | OR<sub>(‐)g</sub> | 0.46 | 0.17‐1.26 |
| | | Present/AA | 27 (25.96) | 34 (32.69) | Ref | Ref | 1 | — |
| **Additive Interaction (RERI)** | | | | | RERI<sub>OR</sub> | 2.32 |
| **GSTT1**|**GSTP1** | Null/ M* | 0 (0) | 1 (0.96) | (df = 1) | 1 | OR<sub>gg</sub> | — | — |
| | | Null/AA | 3 (2.88) | 0 (0) | (df = 1) | 0.088 | OR<sub>(‐)g</sub> | — | — |
| | | Present/ M* | 50 (48.08) | 37 (35.58) | (3.846,df = 1) | OR<sub>(‐)g</sub> | 1.75 | 0.99‐3.06 |
| | | Present/AA | 51 (49.04) | 66 (63.46) | Ref | Ref | 1 | — |
| **Additive Interaction (RERI)** | | | | | RERI<sub>OR</sub> | −0.749 |

Abbreviations: OR: odds ratio; CI: confidence interval; RERI: relative excess risk due to interaction; Ref: reference low‐risk group; M*: AG and GG; Null and M*: susceptibility genotypes.

<sup>a</sup>GSTM1(NG_009246.1).

<sup>b</sup>GSTT1(NM_000853.3).

<sup>c</sup>GSTP1(NG_012075.1).
might depend on geographic and ethnic differences among others (Weich et al., 2016). To our knowledge, no prior studies have been conducted regarding gene–gene and gene–environment interactions and their association with CML risk, drug response, and clinical outcome, especially the relationship between polymorphic chemical metabolizing genes and environmental carcinogens such as cigarette smoke. Thus, we report the impact of GST polymorphisms on CML risk and patients response in the first study from the Iranian population. In our study, a significant relationship was observed between risk to develop CML and GSTM1 and GSTP1 (on additive scale), indicating a meaningful association of these genes on CML susceptibility. These findings are consistent with previous association studies that demonstrated GSTM1/null and GSTP1/GG are predisposing factors to CML susceptibility (Bănescu et al., 2014; Kagita Sailaja, Rao, Rao, & Vishnupriya, 2010). Similar results with our findings were clearly described regarding increased risk of CML for the GSTM1/null genotype by Bhat et al. (2012), Lordelo et al. (2012) and Al-Achkar et al. (2014). In contrast, several studies suggested that GSTM1 may not be predisposing factor for CML risk (Taspinar et al., 2008; Weich et al., 2016). In this study, no association was found between CML risk and GSTT1 polymorphism, consistent with Weich et al. (2016) report, this finding may be due to low frequency of individuals carrying the GSTT1-null genotype or indicating a protective effect of GSTT1/null on CML risk. Contrary to our data, several studies have described increased risk of CML associated with the GSTT1/null genotype in different ethnicities (Özten et al., 2012; Taspinar et al., 2008). In the current study, we analyzed the relationship between dual combinations of gene–gene and gene–environment interactions using ORs as estimated effect in CML risk. Later, we analyzed gene–gene and gene–environment effect in CML risk using RERIOR in an additive model.

**TABLE 4** Gene–environment interactions for different combinations of GSTM1, GSTT1, and GSTP1 genotypes and CML cancer risk

| Genotype   | Smoking | Cases [n(%)] N = 104 | Controls [n(%)] N = 104 | (χ², df) | p-value | OR  | 95% CI |
|------------|---------|----------------------|-------------------------|----------|---------|-----|-------|
| **GSTM1**a |         |                      |                         |          |         |     |       |
| Null +     | 38 (36.54) | 14 (13.47)          | (19.65, 1)              | 0        | ORge   | 6.51| 2.57–15.38 |
| Null –     | 32 (30.77) | 37 (35.57)          | (3.54, 1)               | 0.06     | ORg    | 2.07| 0.96–4.46 |
| Present +  | 19 (18.27)| 17 (16.34)          | (4.84, 1)               | **0.02** | ORg    | 2.68| 1.10–6.52 |
| Present –  | 15 (14.42)| 36 (34.62)          | Ref                     | Ref      | 1      | SI  | 1.99  |
| **Additive Interaction (RERI)** |         |                      |                         |          |         |     |       |
| GSTT1b     |         |                      |                         |          |         |     |       |
| Null +     | 2 (1.92)  | 1 (0.96)             | (1)                     | 0.56     | ORge   | 3.17| 0.28–36.00 |
| Null –     | 1 (0.96)  | 0 (0)                | (1)                     | 0.39     | —      | —   | —     |
| Present +  | 55 (52.88)| 30 (28.85)          | (13.46, 1)              | 0        | ORg    | 2.91| 1.63–5.18 |
| Present –  | 46 (44.24)| 73 (70.19)          | Ref                     | Ref      | 1      | —   | —     |
| **Additive Interaction (RERI)** |         |                      |                         |          |         |     |       |
| GSTP1c     |         |                      |                         |          |         |     |       |
| M* +       | 27 (25.96)| 12 (11.54)          | (12.70, 1)              | 0        | ORge   | 4.40| 1.90–10.19 |
| M* –       | 23 (22.11)| 26 (25)              | (2.1, 1)                | 0.14     | ORg    | 1.73| 0.822–3.65 |
| AA +       | 30 (28.86)| 19 (18.27)          | (8.8, 1)                | **0.003**| ORg    | 3.09| 1.45–6.588 |
| AA –       | 24 (23.07)| 47 (45.19)          | Ref                     | Ref      | 1      | —   | —     |
| **Additive Interaction (RERI)** |         |                      |                         |          |         |     |       |

Bold indicate significant values. Abbreviations: OR, odds ratio; CI, confidence interval; RERI, Relative excess risk due to interaction; Ref, Reference low risk group; AP, attributable proportion of the disease due to interaction; SI, synergy index for interaction; M*: AG, and GG; Null and M*, Susceptibility genotypes.

aGSTM1(NG_009246.1).
bGSTT1(NM_000853.3).
cGSTP1(NG_012075.1).
The findings showed that GSTM1-null and GSTP1M*(AG/GG) together and GSTT1 present are associated with CML development and increased risk especially for GSTM1-null/GSTP1M* genotype is superadditive. This finding is in agreement with other studies (Weich et al., 2016). We carried out further analysis in order to determine the influence of simultaneous presence of GSTs genetic polymorphisms and smoking as an environmental risk factor that its role well has been fixed for lung cancer. Some attractive results were acquired; we showed a proportion of CML cancer attributable to interaction between smoking and GSTM1 null, GSTT1 null, and GSTP1M*genotypes around 42%, 39%, and 13% respectively, furthermore, the relative excess risk due to interaction was 2.75, 1.26, and 0.58 for GSTM1 null, GSTT1 null, and GSTP1M* genotypes, respectively.

In the current study, a significant increase of 6.51-, 3.17-, and 4.40-fold in the probability of having CML in individual who were both smokers and carried GSTM1/null, GSTT1/null and GSTP1M*genotypes, respectively, was indicated. Not many studies have evaluated gene–smoking interaction concerning CML risk to date, except, a recent study that did not find no significant association for susceptibility genotypes to CML risk when smoking was
considered (Özten et al., 2012). In some studies CML risk has been associated with chemical exposures in the shoe-making industry or benzene in Turkey (Yaris, Dikici, Akbulut, Yaris, & Sabuncu, 2004). Pharmacogenetic studies indicated that the detoxifying activity of GSTs enzymes keeps safe cells from the adverse effects of xenobiotics, but may modify drug efficacy in cancer cells, resulting in drug resistance (Kassogue et al., 2014). It is possible that therapy failure in the presence of the GSTM1/null and GSTP1/GG genotype may be related to pathways necessary for the activation of kinases to induce apoptosis (Weich et al., 2016). Therefore, we examined the role of GSTs genetic polymorphisms on TKIs response. Our data suggest that patients with GSTM1‐null and GSTP1 AG/GG genotypes have significantly a lower rate of MMR achievement, and also have a lower rate of CCyR at 6 months. No association was found for GSTT1. This finding concerning GSTM1 null genotype is consistent with a recent study that GSTM1/null was associated with Imatinib (Gleevec) failure (Davies et al., 2014). In contrast, the recent report by Weich et al. (2016) showed a lower rate of MMR and EFS for GSTM1/present patients, and also indicated treatment failure for GSTP1/GG genotype compared to GSTP1/ AA + AG genotype (Weich et al., 2016). Regarding probability of EFS during treatment, no association was found in patients with GSTM1/null and GSTP1*M genotype compared to GSTM1/present and GSTP1/ AA genotypes. These findings are not agreement with report of Weich et al. (2016). In conclusion, our study suggests the influence of GSTM1 and GSTP1 polymorphisms on CML risk and treatment response, and also the interaction between GSTs polymorphisms and smoking plays a significant role on CML susceptibility.

**ACKNOWLEDGMENT**

We are grateful for the help and collaboration of the patients and for their participation in the study.

**CONFLICT OF INTEREST**

The authors declare that they have no conflict of interest.

**AUTHOR CONTRIBUTIONS**

GR: performed the experiments, analyzed the data, and wrote manuscript, DA: assisted in final revision of manuscript, FG: performed the experiments, MH: designed the study and assisted in revision of manuscript, AK: assisted in analysis and interpretation of data, HJ: provided the CML samples and clinical data, and revised manuscript, RAK: assisted in collection of CML samples and clinical data, and all authors reviewed and provided final approval for the paper.

**ORCID**

Mohammad Hamid https://orcid.org/0000-0002-4625-0713
REFERENCES

Al-Achkar, W., Azegis, G., Moassass, F., & Wafa, A. (2014). Influence of CYP1A1, GST polymorphisms and susceptibility risk of chronic myeloid leukemia in Syrian population. *Medical Oncology, 31*, 889. https://doi.org/10.1007/s12032-014-0889-4

Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., ... Hehlmann, R. (2009). Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *Journal of Clinical Oncology, 27*, 6041–6051. https://doi.org/10.1200/JCO.2009.25.0779.

Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Al-Achkar, W., Azeiz, G., Moassass, F., & Wafa, A. (2014). Influence of CYP1A1, GST polymorphisms and susceptibility risk of chronic myeloid leukemia in Syrian population. *Medical Oncology, 31*, 889. https://doi.org/10.1007/s12032-014-0889-4.

Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., & Appelbaum, F. (2006). Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood, 108*, 1809–1820. https://doi.org/10.1182/blood-2006-02-005686.

Bănescu, C., Trifă, A. P., Voidzădn, S., Moldovan, V. G., Macarie, I., Lazar, E. B., ... Dobreanu, M. (2014). CAT, GPX1, MnSOD, GSTM1, GSTT1, and GSTP1 genetic polymorphisms in chronic myeloid leukemia: A case-control study. *Oxidative Medicine Cellular Longevity, 2014*, 1–6. https://doi.org/10.1155/2014/875861.

Bhat, G., Bhat, A., Wani, A., Sadiq, N., Jeelani, S., Kaur, R., ... Ganai, B. (2012). Polymorphic variation in glutathione-S-transferase genes and risk of chronic myeloid leukaemia in the Kashmiri population. *Asian Pacific Journal of Cancer Prevention, 13*, 69–73.

Bruzzoni-Giovanelli, H., González, J. R., Siguax, F., Villoutreix, B. O., Cayuela, J. M., Guilhot, J., ... Rousselot, P. (2015). Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. *Oncotarget, 6*, 36269–36277. https://doi.org/10.18632/oncotarget.5915.

Cross, N. C. (2009). Standardisation of molecular monitoring for chronic myeloid leukaemia. *Best Practice & Research Clinical Haematology, 22*, 355–365. https://doi.org/10.1016/j.beha.2009.04.001.

Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., ... Clark, R. E. (2014). Dual glutathione-S-transferase-01 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia. *Clinical Pharmacology & Therapeutics, 96*, 694–703. https://doi.org/10.1038/clpt.2014.176.

Dusinska, M., Staruchova, M., Horska, A., Smolkova, B., Collins, A., Bonassi, S., & Volkova, K. (2012). Are glutathione S transferases involved in DNA damage signalling? Interactions with DNA damage and repair revealed from molecular epidemiology studies. *Mutation Research, 736*, 130–137. https://doi.org/10.1016/j.mrfmmm.2012.03.003.

Eghtedar, A., Kantarjian, H., Jabbour, E., O’Brien, S., Burton, E., Garcia-Manero, G., ... Cortes, J. (2013). Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. *Clinical Lymphoma, Myeloma & Leukemia, 13*, 477–484. https://doi.org/10.1016/j.clml.2013.02.025.

Francis, S., Lucas, C., Lane, S., Wang, L., Watmough, S., Knight, K., ... Clark, R. E. (2013). A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. *Leukemia Research, 37*, 752–758. https://doi.org/10.1016/j.leukres.2013.04.003.

Hayes, J. D., Flanagan, J. U., & Jowsey, I. R. (2005). Glutathione transferases. *Annual Review of Pharmacology and Toxicology, 45*, 51–88. https://doi.org/10.1146/annurev.pharmtox.45.120403.095857.

He, H.-R., Zhang, X.-X., Sun, J.-Y., Hu, S.-S., Ma, Y., Dong, Y.-L., & Lu, J. (2014). Glutathione S-transferase gene polymorphisms and susceptibility to chronic myeloid leukemia. *Tumour Biology, 35*, 6119–6125. https://doi.org/10.1007/s13277-014-1810-7.

Hollman, A. L., Tchounwou, P. B., & Huang, H. C. (2016). The association between gene-environment interactions and diseases involving the human GST superfamily with SNP variants. *International Journal of Environmental Research and Public Health, 13*, E379. https://doi.org/10.3390/ijerph13040379.

Jiang, Z., & VanderWeele, T. J. (2014). Additive interaction in the presence of a mismeasured outcome. *American Journal of Epidemiology, 181*, 81–82. https://doi.org/10.1093/aje/kwu351.

Kagita Sailaja, D., Rao, D. N., Rao, D. R., & Vishnu priya, S. (2010). Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia. *Asian Pacific Journal of Cancer Prevention, 11*, 461–464.

Kassogué, Y., Quachouh, M., Dehbi, H., Quessar, A., Benchekroun, S., & Nadifi, S. (2014). Effect of interaction of glutathione S-transferases (T1 and M1) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib. *Medical Oncology, 31*, 47. https://doi.org/10.1007/s12032-014-0047-z.

Khoury, M. J., & Flanders, W. D. (1996). Nontraditional epidemiologic approaches in the analysis of gene environment interaction: Case-control studies with no controls!. *American Journal of Epidemiology, 144*, 207–213. https://doi.org/10.1093/oxfordjourn als.aje.a1008915.

Laborde, E. (2010). Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. *Cell Death & Differentiation, 17*, 1373–1380. https://doi.org/10.1038/cdd.2010.80.

Lordelo, G. S., Miranda-Vilela, A. L., Akimoto, A. K., Alves, P., Hiragi, C. O., Nonino, A., ... Grisolia, C. K. (2012). Association between methylene tetrahydropfolate reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. *Genetics and Molecular Research, 11*, 1013–1026. https://doi.org/10.4238/2012.April.19.6.

Miller, S., Dykes, D., & Polesky, H. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Research, 16*, 1215. https://doi.org/10.1093/nar/16.3.1215.

Müller, M. C., Cross, N. C. P., Erben, P., Schenk, T., Hanfstein, B., Ernst, T., ... Hochhaus, A. (2009). Harmonization of molecular monitoring of CML therapy in Europe. *Leukemia, 23*, 1957–1963. https://doi.org/10.1038/leu.2009.168.

Özten, N., Sunguroğlu, A., & Bosland, M. C. (2012). Variations in glutathione-S-transferase genes influence risk of chronic myeloid leukemia. *Hematological Oncology, 30*, 150–155. https://doi.org/10.1002/hon.1018.

Rostami, G., Hamid, M., Yaran, M., Khani, M., & Karimipoor, M. (2015). Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib. *Journal of Human Genetics, 60*, 253–258. https://doi.org/10.1038/jhg.2015.11.

Soylemez, F., Akbas, E., Seyrek, E., Mutluhan, H., & Camdeviren, H. (2006). The relationship between the risk of lung cancer and the exon 5 (ILE105VAL) polymorphism of glutathione S-transferase P1 (GSTP1) gene. *Turkish Journal of Cancer, 36*, 5–10.
Taspinar, M., Aydos, S. E., Gomez, O., Elhan, A. H., Karabulut, H. G., & Sunguroglu, A. (2008). CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukaemia. *Swiss Medical Weekly, 138*, 12–17. 2008/01/smw-12036.

Walter, S., & Holford, T. (1978). Additive, multiplicative, and other models for disease risks. *American Journal of Epidemiology, 108*, 341–346.

Weich, N., Ferri, C., Moiraghi, B., Bengió, R., Giere, I., Pavlovsky, C., … Fundia, A. F. (2016). GSTM1 and GSTP1, but not GSTT1 genetic polymorphisms are associated with chronic myeloid leukemia risk and treatment response. *Cancer Epidemiology, 44*, 16–21. https://doi.org/10.1016/j.canep.2016.07.008.

Yaris, F., Dikici, M., Akbulut, T., Yaris, E., & Sabuncu, H. (2004). Story of benzene and leukemia: epidemiologic approach of Muzaffer Aksoy. *Journal of Occupational Health, 46*, 244–247. https://doi.org/10.1539/joh.46.244.

Yaya, K., Hind, D., Meryem, Q., Asma, Q., Said, B., & Sellama, N. (2014). Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia. *Tumour Biology, 35*, 10969–10975. https://doi.org/10.1007/s13277-014-2400-4.

---

**How to cite this article:** Rostami G, Assad D, Ghadyani F, et al. Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response. *Mol Genet Genomic Med*. 2019;7:e717. https://doi.org/10.1002/mgg3.717